A double blind randomised placebo controlled pilot study of oral co-trimoxazole in advanced fibrotic lung disease
Introduction
Idiopathic interstitial pneumonia (IIP) belongs to the group of interstitial lung diseases that result in pulmonary inflammation and fibrosis [1], [2]. The clinical picture is one of progressive dyspnoea and respiratory failure. The American Thoracic Society (ATS)/European Respiratory Society (ERS) reviewed and defined the clinical and pathological diagnosis and management of these diseases (joint statement February 2000) [3]. It clarified the main subtypes from biopsy or high resolution CT (HRCT) scanning of the chest. As less than 25% of the UK patients with IIP are biopsied, histological subtypes were often unknown [4], [5] and clinically indistinguishable [6]. Comparative studies show sufficient correlation to allow HRCT to replace biopsy in a high percentage of cases [7], [8]. Usual interstitial pneumonia (UIP) is the commonest sub type in the UK (mean survival of 5 years) [9], [10]. A recent Cochrane meta-analysis of IPF/UIP found no convincing evidence that immunosuppression with steroids and other agents resulted in disease regression or improved survival [11], [12]. UK studies demonstrated that 65% of patients receive these treatments despite the view of clinicians that their efficacy is poor [13], [14].
In 1996, a 50 year old man with advanced fibrotic lung disease awaiting lung transplant was admitted with severe hypoxaemia and dyspnoea. His past treatment included daily oral prednisolone and monthly pulsed methyl-prednisolone and cyclophosphamide. Despite this he had a progressive downhill course with dyspnoea at a few feet.
On admission, fevers with severe hypoxaemia and increased cough raised the possibility of infection with pneumocystis due from long-term immunosuppression. Bronchoscopy was impossible on clinical grounds so high dose oral co-trimoxazole was commenced. Oxygen requirements reduced from 15 L/min to zero within 7 days. At 14 days the patient was well with minimal exertional dyspnoea. Bronchoscopy then returned negative for pneumocystis on silver-stain. To date his clinical state remains stable on co-trimoxazole 480 mg od. In 2002 histological review of his biopsies from two reference centres gave different diagnoses (NSIP and DIP).
Between 1998 and 2000, 14 patients judged to be dying from end stage fibrotic IIP (CT diagnosis 50% UIP and 50% fibrotic NSIP) were admitted to St Helier Hospital on conventional steroid treatment. Treatment with co-trimoxazole was commenced on verbal consent, resulting in improvements within 5 days and discharged in 2 weeks. Doses of co-trimoxazole were gradually lowered in subsequent patients to reduce gastric fullness and dyspepsia. A single case report (1998) of desquamative interstitial pneumonitis recurring in a single lung transplant recipient which resolved on co-trimoxazole treatment was identified from the literature [15].
From our observations, a double blind randomised placebo controlled pilot study was designed. This study would examine IIP patients with progressive fibrotic lung disease of mixed subtypes where oxygen desaturation on exercise could be fully assessed by the shuttle walking test and other measures impossible for end stage patients. This publication describes the pilot study and includes ongoing follow up data ‘out of study’.
Section snippets
Method
This study was approved by the local regional ethical committee, with written informed consent from the patients and their general practitioners.
Results
Patient characteristics & HRCT patterns (Table 1): All sputum samples were negative for pneumocystis and common pathogens on culture.
Discussion
The pilot study was designed to test the observations that patients with progressive fibrotic lung disease (IIP) did improve with co-trimoxazole. The current study includes patients with IIP with of a variety of HRCT patterns (predominantly UIP and fibrotic NSIP). On clinical grounds all groups of patients were indistinguishable, but symptomatic with cough, poor life quality and alarming reductions in exercise tolerance with time.
The study findings demonstrate improvement in exercise capacity
Conclusion
This pilot study examines an antibiotic not previously used in the treatment of progressive fibrotic lung disease. The findings show significant improvements in objective and subjective parameters, which fulfil the ATS/ERS criteria of a response to treatment. Since patients with progressive fibrotic lung disease are clinically difficult for doctors to manage, co-trimoxazole may be an inexpensive and helpful agent; improving life quality and exercise capacity with benefit seen after 2 weeks.
Acknowledgements
The authors thank Peel Trust Fund for funding of oral co-trimoxazole and placebo tablets, R & D St Helier for funding out of study repeat HRCT scans only. The authors also thanks the Pharmacy for randomisation and drug issue and the patients for their good humour and reliable attendance on Saturday mornings. Thanks are also to Alex Nicholas (B.Sc., M.Sc.) and Rod Lunn (B.Sc., M.Sc.) for cytokine analysis and to Jenny Swallow for preparation of the manuscript. The authors gratefully acknowledges
References (30)
- et al.
Corticosteroids for idiopathic pulmonary fibrosis
Cochrane Database Systematic Rev
(2003) - et al.
Vascular endothelial growth gene, polymorphism and acute respiratory distress syndrome
Thorax
(2005) - et al.
Detection of Pneumocystis Carinii and characterisation of mutations associated with sulpha resistance in BAL samples from human immunodeficiency virus infected subjects
J Clin Micro
(2003) - et al.
Clinical pharmacokinetics of sulfonamides
Chemother J
(1997) - et al.
Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis
Eur Respir J
(2001) - et al.
The epidemiology of interstitial lung disease
Am J Respir Crit Care Med
(1994) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society and the European Respiratory Society
Am J Respir Crit Care Med
(2000)- et al.
Idiopathic pulmonary fibrosis—clinical relevance of pathologic classification
Am J Respir Crit Care Med
(1998) - et al.
The management of cryptogenic fibrosing alveolitis in three regions of the United Kingdom
Eur Respir J
(1993) - et al.
Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis
Am J Respir Crit Care Med
(1998)
CT evaluation of fibrosing alveolitis—applications and in sights
J Thoracic Imaging
CT evaluation of fibrosing alveolitis—applications and in sights
Eur Respir J
Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances and diagnostic accuracy of thin section CT
Radiology
Radiological versus histological diagnosis in UIP and NSIP: survival implications
Thorax
Survival in patients with cryptogenic fibrosing alveolitis—a population based cohort study
Chest
Immunomodulatory agents for idiopathic pulmonary fibrosis
Cochrane Database Systematic Rev
Cited by (42)
Idiopathic pulmonary fibrosis
2017, The LancetCitation Excerpt :Studies into whether antimicrobials might influence the idiopathic pulmonary fibrosis disease course are ongoing. A phase 2 study of cotrimoxazole was done in patients with fibrotic idiopathic interstitial pneumonia following the observation of a clinical improvement in patients with advanced fibrotic lung disease treated with long-term oral cotrimoxazole.131,132 No difference was identified in the primary endpoint of change in forced vital capacity over 12 months; however, a possible reduction in mortality was observed in patients who adhered to treatment.
Lung microbiome and disease progression in idiopathic pulmonary fibrosis: An analysis of the COMET study
2014, The Lancet Respiratory MedicineErratum: Emergency oxygen therapy: Do medical students know more than doctors? (Thorax (2012) 67:2 (A168) DOI: 10.1136/thoraxjnl-2012-202678.298corr1)
2013, ThoraxCitation Excerpt :This may be due to antibiotic mechanisms. In a previous pilot study of 20 patients with IIP, co-trimoxazole treatment improved forced vital capacity (FVC), shuttle walk distance and Medical Research Council (MRC) dyspnoea score over 3 months.5 We therefore conducted a larger clinical trial to compare the efficacy and safety of the addition of 12 months of oral co-trimoxazole to standard treatment for fibrotic IIP.
Erratum: Patient satisfaction during endobronchial ultrasound-guided transbronchial needle aspiration performed under mild conscious sedation (Thorax (2012) 67:2 (A94) DOI: 10.1136/thoraxjnl-2012-202678.313corr1)
2013, ThoraxCitation Excerpt :This may be due to antibiotic mechanisms. In a previous pilot study of 20 patients with IIP, co-trimoxazole treatment improved forced vital capacity (FVC), shuttle walk distance and Medical Research Council (MRC) dyspnoea score over 3 months.5 We therefore conducted a larger clinical trial to compare the efficacy and safety of the addition of 12 months of oral co-trimoxazole to standard treatment for fibrotic IIP.
Erratum: A retrospective study of changing performance status and staging in all patients presenting with lung cancer to the northern health and social care trust over the past decade (Thorax (2012) 67:2 (A137) DOI: 10.1136/thoraxjnl-2012-202678.232corr1)
2013, ThoraxCitation Excerpt :This may be due to antibiotic mechanisms. In a previous pilot study of 20 patients with IIP, co-trimoxazole treatment improved forced vital capacity (FVC), shuttle walk distance and Medical Research Council (MRC) dyspnoea score over 3 months.5 We therefore conducted a larger clinical trial to compare the efficacy and safety of the addition of 12 months of oral co-trimoxazole to standard treatment for fibrotic IIP.
Erratum: Hot off the breath: Omalizumab: NICE to USE you, to LOSE you NICE (Thorax (2013) 68 (7-8) DOI: 10.1136/thoraxjnl-2012-202969)
2013, ThoraxCitation Excerpt :This may be due to antibiotic mechanisms. In a previous pilot study of 20 patients with IIP, co-trimoxazole treatment improved forced vital capacity (FVC), shuttle walk distance and Medical Research Council (MRC) dyspnoea score over 3 months.5 We therefore conducted a larger clinical trial to compare the efficacy and safety of the addition of 12 months of oral co-trimoxazole to standard treatment for fibrotic IIP.